HUP0103797A2 - TPL-2/COT kináz és alkalmazásai - Google Patents

TPL-2/COT kináz és alkalmazásai Download PDF

Info

Publication number
HUP0103797A2
HUP0103797A2 HU0103797A HUP0103797A HUP0103797A2 HU P0103797 A2 HUP0103797 A2 HU P0103797A2 HU 0103797 A HU0103797 A HU 0103797A HU P0103797 A HUP0103797 A HU P0103797A HU P0103797 A2 HUP0103797 A2 HU P0103797A2
Authority
HU
Hungary
Prior art keywords
tpl
compound
compounds
polypeptide
activity
Prior art date
Application number
HU0103797A
Other languages
English (en)
Hungarian (hu)
Inventor
Hamish John Allen
Monica Polidoro Belich
Richard Woodward Dixon
Leland Herries Johnston
Joanne Sara Kamens
Steven Charles Ley
Andres Salmeron
Dineli Wickramasinghe
Yajun Xu
Original Assignee
Abbott Gmbh & Co. Kg
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9817930.2A external-priority patent/GB9817930D0/en
Priority claimed from GBGB9827712.2A external-priority patent/GB9827712D0/en
Application filed by Abbott Gmbh & Co. Kg, Medical Research Council filed Critical Abbott Gmbh & Co. Kg
Publication of HUP0103797A2 publication Critical patent/HUP0103797A2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
HU0103797A 1998-08-18 1999-08-13 TPL-2/COT kináz és alkalmazásai HUP0103797A2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9817930.2A GB9817930D0 (en) 1998-08-18 1998-08-18 Pathway
GBGB9827712.2A GB9827712D0 (en) 1998-12-16 1998-12-16 Pathway
PCT/US1999/018543 WO2000011191A2 (en) 1998-08-18 1999-08-13 Tpl-2/cot kinase and methods of use

Publications (1)

Publication Number Publication Date
HUP0103797A2 true HUP0103797A2 (hu) 2003-10-28

Family

ID=26314223

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103797A HUP0103797A2 (hu) 1998-08-18 1999-08-13 TPL-2/COT kináz és alkalmazásai

Country Status (22)

Country Link
US (1) US20020099169A1 (enExample)
EP (1) EP1105501A2 (enExample)
JP (1) JP4719831B2 (enExample)
KR (1) KR20010085407A (enExample)
CN (1) CN1323346A (enExample)
AU (1) AU767973B2 (enExample)
BG (1) BG105345A (enExample)
BR (1) BR9913070A (enExample)
CA (1) CA2339036A1 (enExample)
CZ (1) CZ2001625A3 (enExample)
HK (1) HK1041901A1 (enExample)
HU (1) HUP0103797A2 (enExample)
ID (1) ID28955A (enExample)
IL (1) IL141355A0 (enExample)
MX (1) MXPA01001747A (enExample)
NO (1) NO20010786L (enExample)
NZ (1) NZ510313A (enExample)
PL (1) PL347137A1 (enExample)
RU (1) RU2001107122A (enExample)
SK (1) SK2242001A3 (enExample)
TR (2) TR200103840T2 (enExample)
WO (1) WO2000011191A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660906B1 (en) 2000-03-08 2003-12-09 Thomas Jefferson University Tpl2 transgenic knockout mice
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
GB0402661D0 (en) * 2004-02-06 2004-03-10 Medical Res Council TPL2 and its expression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
UA71889C2 (uk) * 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування

Also Published As

Publication number Publication date
ID28955A (id) 2001-07-19
TR200103840T2 (tr) 2002-06-21
NO20010786D0 (no) 2001-02-16
PL347137A1 (en) 2002-03-25
IL141355A0 (en) 2002-03-10
NZ510313A (en) 2003-11-28
EP1105501A2 (en) 2001-06-13
CA2339036A1 (en) 2000-03-02
AU5563399A (en) 2000-03-14
BR9913070A (pt) 2001-05-08
RU2001107122A (ru) 2003-04-20
KR20010085407A (ko) 2001-09-07
SK2242001A3 (en) 2001-10-08
BG105345A (en) 2001-12-31
CZ2001625A3 (cs) 2002-02-13
HK1041901A1 (zh) 2002-07-26
JP2002531058A (ja) 2002-09-24
MXPA01001747A (es) 2003-06-06
JP4719831B2 (ja) 2011-07-06
US20020099169A1 (en) 2002-07-25
WO2000011191A2 (en) 2000-03-02
NO20010786L (no) 2001-04-17
CN1323346A (zh) 2001-11-21
WO2000011191A3 (en) 2000-06-08
TR200100624T2 (tr) 2001-08-21
AU767973B2 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
JP6025758B2 (ja) Nfatの制御因子
JP4685241B2 (ja) 疾患の処置に有用な細胞表面膜受容体のモジュレーターを同定する方法
US6630297B2 (en) Methods of screening for agents that modulate the interaction of human ECT2 polypeptide with an ECT2 binding target
CA2054602C (en) Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system
US6171781B1 (en) NF-AT polypeptides and polynucleotides
US20040053841A1 (en) Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US20040101879A1 (en) Srebp pathway modulation through targeting hisrs
WO2004033666A2 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
US6066463A (en) Method and compositions for treatment of BCR-ABL associated leukemias and other cell proliferative disorders
Hirai et al. SH2 mutants of c-src that are host dependent for transformation are trans-dominant inhibitors of mouse cell transformation by activated c-src.
US8809500B2 (en) Complexes comprising mammalian raptor polypeptide and mammalian mTOR polypeptide
AU767973B2 (en) TPL-2/COT kinase and methods of use
US20030219427A1 (en) TPL-2/COT kinase and methods of use
ZA200102200B (en) TPL-2/cot kinase and methods of use.
EP1294872B1 (en) Human trp-like calcium channel protein-2 (tlcc-2)
US20080199469A1 (en) Regulation and function of TPL-2
US20070117143A1 (en) Atm related kinase atx, nucleic acids encoding same and methods of use
JP2002508180A (ja) ヒトrad1核酸、ポリペプチド、検定、治療方法および手段
JP4279524B2 (ja) Ark5
EP1125946A1 (en) Cell adhesion therapy through modulation of a Rap family member or of a GEF (guanine nucleotide exchange factor)
Hochrein Probing the conformational changes in Hck, a Src-family kinase, using hydrogen exchange mass spectrometry
Sosinowski Src-like adaptor protein negatively regulates T cell receptor signaling and thymocyte development
WO2003104475A2 (en) Atm related kinase atx, nucleic acids encoding same and methods of use

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees